Importantly, the largest reductions in BMI were observed in the southern United States, which also reported the highest rates of GLP-1 RA dispensing claims (Rader et al., 2024), a geographic concordance that is consistent with a causal contribution of these pharmacotherapies to the observed population-level BMI decline
We also note that, while NRS, BRAF-NRS, and FAS have been validated in some disorders, currently there is no single fatigue behavioral instrument that has been validated in both hypothyroidism and CFS
(PubMed) Turunen M, Wehlin L, Sjoberg M, et al
Fig .2 Potential adverse effects associated with GLP1-RAs
Manufactured in a facility that produces products containing milk, eggs, fish, shellfish, tree nuts, wheat, and soy.